Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Lonza Signs Deal with Swedish Start-up
4:26 AM MDT | March 17, 2011 | Alex Scott
Lonza says it has signed a deal to provide development and cGMP manufacturing services for Athera (Solna, Sweden), a start-up biotech company. Financial terms were not disclosed. Athera is part of Karolinska Development (Solna), a group which has a portfolio of more than 40 pharmaceutical companies. Lonza says it will initiate cell line and process development, using its GS Gene expression system for Athera’s monoclonal antibody, PC-mAb, a developmental drug intended for the treatment of patients with acute coronary syndrome (ACS). People with ACS...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee